<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03296163</url>
  </required_header>
  <id_info>
    <org_study_id>MB02-C-02-17</org_study_id>
    <nct_id>NCT03296163</nct_id>
  </id_info>
  <brief_title>A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <acronym>STELLA</acronym>
  <official_title>A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>mAbxience S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>mAbxience S.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, multinational, double-blind, 1:1 randomized, parallel-group,
      equivalence Phase 3 study to compare the efficacy and safety of MB02 plus chemotherapy
      (carboplatin and paclitaxel) versus Avastin® plus chemotherapy (carboplatin and paclitaxel)
      in subjects with Stage IIIB/IV non-squamous NSCLC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy parameters, safety profiles and immunogenicity will be compared between MB02
      (Bevacizumab Biosimilar Drug) and EU-approved Avastin®
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Actual">July 3, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) at Week 18</measure>
    <time_frame>18 weeks from randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) at Week 18 and at Week 52</measure>
    <time_frame>At Week 18 and at Week 52 from randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) at Week 18 and at Week 52</measure>
    <time_frame>At Week 18 and at Week 52 from randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Safety profile (incidence, nature, and severity of adverse events (AEs) graded according to NCI-CTCAE; v4.03)</measure>
    <time_frame>Week 1 to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Assessments (Anti-drug Antibodies)</measure>
    <time_frame>At Weeks 1, 3, 9, 18, 34 and 52 from randomisation and, at the End of Treatment Visit if, an ADA sample has not been collected within the previous 3 weeks</time_frame>
    <description>Incidence of anti-drug (bevacizumab) antibodies (ADA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Assessments (Neutralizing Antibodies)</measure>
    <time_frame>At Weeks 1, 3, 9, 18, 34 and 52 from randomisation and, at the End of Treatment Visit if, an Nab sample has not been collected within the previous 3 weeks</time_frame>
    <description>Incidence of anti-drug (bevacizumab) antibodies (ADA) - neutralizing antibodies (Nab)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">627</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>MB02 (Bevacizumab Biosimilar Drug)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MB02 (Bevacizumab Biosimilar Drug) + Carboplatin/Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU-approved Avastin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU-approved Avastin® + Carboplatin/Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB02 (Bevacizumab Biosimilar Drug)</intervention_name>
    <description>15 mg/kg IV every 3 weeks on Day 1</description>
    <arm_group_label>MB02 (Bevacizumab Biosimilar Drug)</arm_group_label>
    <other_name>Bevacizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EU-approved Avastin®</intervention_name>
    <description>15 mg/kg IV every 3 weeks on Day 1</description>
    <arm_group_label>EU-approved Avastin®</arm_group_label>
    <other_name>Bevacizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 6 IV every 3 weeks on Day 1 6 cycles</description>
    <arm_group_label>EU-approved Avastin®</arm_group_label>
    <arm_group_label>MB02 (Bevacizumab Biosimilar Drug)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles</description>
    <arm_group_label>EU-approved Avastin®</arm_group_label>
    <arm_group_label>MB02 (Bevacizumab Biosimilar Drug)</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and female subjects aged ≤ 18 years to ≤ 80 years.

          2. Signed informed consent must be obtained before initiation of any study-specific
             procedures or treatment as confirmation of the subject's awareness and willingness to
             comply with the study requirements.

          3. Subjects should have newly diagnosed or recurrent Stage IIIB/IV (defined by seventh
             edition of the TNM classification for Lung Cancer, 2010) non-squamous NSCLC not
             amenable to curative intent surgery, and not have received any systemic therapy for
             advanced disease (exclusion criteria 3 and 4). For subjects with recurrent disease, at
             least 6 months must have elapsed before randomization from previous adjuvant
             treatment.

          4. Previous radiation therapy if completed &gt;4 weeks before randomization. Palliative
             radiotherapy to bone lesions is allowed if completed &gt;2 weeks of randomization.

          5. Subjects must have at least 1 unidimensional measurable lesion per RECIST version 1.1
             (assessed locally).

          6. Subjects must have an ECOG performance status ≤1 at Screening.

          7. Subjects must have adequate hepatic, renal and hematologic function defined as:

               -  Hepatic function: bilirubin level &lt;1.5 ULN, ALT and AST levels&lt;2.5×ULN.

               -  Renal function: serum creatinine level &lt;1.5×ULN, calculated creatinine clearance
                  (CrCl) &gt;30 mL/min (Cockroft-Gault formula), urine protein to creatinine ratio &lt;1.
                  Subjects with urine protein-to-creatinine ratio &gt;1 may be enrolled if they have
                  &lt;1 g of protein in 24-hour urine collection.

               -  Hematological function: Absolute neutrophil count &gt;1.5×109 /L; platelets &gt;100×109
                  /L, hemoglobin (Hb) &gt;9 g/dL.

               -  Adequate coagulation parameters such as: INR ≤ 2.0 and aPTT ≤ 1.5 x ULN within 7
                  days prior to randomization for patients not receiving anticoagulation therapy.

          8. Eligible subjects must have a systolic blood pressure of ≤ 140 mm Hg and a diastolic
             blood pressure of &lt; 100 mm Hg at screening.

          9. Women of childbearing potential, and their partners, must agree to adhere to pregnancy
             prevention methods throughout the duration of the study (including the Follow-up
             visits, where applicable). Women of childbearing potential are defined as those who
             are not surgically sterile (did not underwent bilateral tubal ligation, bilateral
             oophorectomy, or hysterectomy) and not postmenopausal.

        Subjects and their partners must agree to use a highly effective method of contraception,
        to avoid women becoming pregnant throughout the course of the study. Medically acceptable
        forms of birth control can include the following, with approval of the treating physician:

          -  Combined (estrogen and progestogen containing) hormonal contraception associated with
             inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only
             hormonal contraception associated with inhibition of ovulation (oral, injectable,
             implantable), intrauterine device, intrauterine hormone-releasing system, bilateral
             tubal occlusion, vasectomised partner, sexual abstinence.

             10. Non fertile women can be included, that is, those who are physiologically
             incapable of becoming pregnant, because of:

          -  Hysterectomy.

          -  Bilateral oophorectomy (ovariectomy).

          -  Bilateral tubal ligation or,

          -  Postmenopausal women defined as:

        Subjects not using HRT and have experienced total cessation of menses for ≥ 1 year and be
        greater than 45 years of age, OR, in questionable cases, have a follicle stimulating
        hormone &gt;40 mIU/mL and an estradiol value &lt;40 pg/mL (&lt;140 pmol/L).

        Subjects must discontinue HRT before study enrolment because of the potential for
        inhibition of cytochrome enzymes that metabolize estrogens and progestins. For most forms
        of HRT, at least 2 to 4 weeks must elapse between the cessation of HRT and determination of
        menopausal status; the length of this interval depends on the type and dosage of HRT.

        If a female subject is determined not to be postmenopausal, that subject must use adequate
        contraception, as defined immediately above (inclusion 8).

        Exclusion Criteria:

          1. Inability to comply with protocol procedures.

          2. Participation in another clinical trial or treatment with another investigational
             agent within 4 weeks or 5 half-lives of investigational agent before randomization,
             whichever is longer.

          3. Subjects previously treated with monoclonal antibodies or small molecule inhibitors
             against VEGF or VEGF receptors, including Avastin®.

          4. Subjects who have received previous chemotherapy, immunotherapy, targeted therapy, or
             biological therapy for their lung cancer. Note: Adjuvant and neo- adjuvant therapy are
             permitted (see: inclusion criterion 3).

          5. Subjects who have known central nervous system disease, with the exception of subjects
             with treated brain metastases who have completed treatment (radiation, surgery or
             stereotactic surgery) and have not received steroids for at least 4 weeks before
             randomization. Subjects with central nervous system metastases treated by
             neurosurgical resection or brain biopsy performed within 8 weeks before randomization
             will be excluded. Subjects with known or history of brain metastases must undergo
             brain imaging during screening.

          6. Current or recent (within 10 days of the first dose of study treatment) use of aspirin
             (at least 325 mg/day) or other nonsteroidal anti-inflammatory drugs with antiplatelet
             activity or treatment with dipyridamole (Persantine®), ticlopidine (Ticlid®),
             clopidogrel (Plavix®), or cilostazol (Pletal®).

          7. Current or recent (within 5 days) use of therapeutic anticoagulation or use of
             thrombolytic agent. Prophylactic use of low molecular weight heparin is allowed.

          8. Subjects with an INR &gt;2, unless receiving active anticoagulation treatment, will be
             excluded.

          9. Subjects who have a diagnosis of small cell carcinoma of the lung or squamous cell
             carcinoma of the lung. Mixed tumors should be categorized according to the predominant
             histology. If small cell elements are present, the subject will be excluded.

         10. Subjects with known tumors that harbor activating epidermal growth factor receptor and
             anaplastic lymphoma receptor tyrosine kinase (assessed locally).

         11. Subjects who have a history of hypersensitivity to the active substance (bevacizumab,
             carboplatin, and/or paclitaxel) or any of the excipients (such as trehalose dehydrate,
             sodium phosphate, or polysorbate 20).

         12. Subjects with known active viral infection: hepatitis B, hepatitis C, or HIV.

         13. Subjects who are pregnant or breastfeeding. Women of child-bearing potential must have
             a negative pregnancy test at Screening.

         14. Subjects with previous major surgery, open biopsy, open pleurodesis, or significant
             traumatic injury within 4 weeks before randomization or those anticipated to require
             major surgery during the study.

         15. Subjects who have had a core biopsy taken or have had another minor surgical
             procedure, excluding placement of vascular access device, closed pleurodesis,
             thoracentesis, and mediastinoscopy, within 1 week of randomization.

         16. Subjects with a history of abdominal fistula, GI perforation, intra-abdominal abscess
             within 6 months of randomization.

         17. Subjects with a nonhealing wound, active ulcer, or untreated bone fracture.

         18. Subjects with previous history of hypertensive crisis or hypertensive encephalopathy.

         19. Subjects with New York Heart Association Grade II or greater congestive heart failure,
             or angina, myocardial infarction within 6 months before randomization; symptomatic
             arrhythmia or serious cardiac arrhythmia requiring medication; abnormal left
             ventricular ejection fraction &lt; 50% assessed by ultrasound or multigated acquisition
             scan.

         20. Subjects with a previous malignancy within 3 years of randomization (other than
             superficial basal cell and superficial squamous (skin) cell carcinoma, or carcinoma in
             situ of the uterine cervix, bladder, or prostate).

         21. Subjects with history of a significant vascular event within 6 months before
             randomization (including, but not limited to myocardial infarction and stroke or
             transient ischemic attack).

         22. Subjects with known bleeding diathesis or significant coagulopathy within 3 months
             before randomization.

         23. Subjects with history of grade ≥2 hemoptysis within 6 months before randomization
             (≥0.5 teaspoons of bright red blood per event).

         24. Subjects with a tumor(s) invading or compressing major blood vessels.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MedRadius</name>
      <address>
        <city>Maceió</city>
        <state>AL</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Câncer do Ceará - ICC</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Brasileiro de Radioterapia Oncologia e Mastologia</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Erasto Gaertner - Paranaense de Combate ao Câncer</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancer- INCA</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa e Educação da Serra Gaúcha (CEPESG)</name>
      <address>
        <city>Caxias do Sul</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPCEM Universidade de Caxias Do Sul</name>
      <address>
        <city>Caxias do Sul</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Caridade de Ijuí</name>
      <address>
        <city>Ijuí</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Câncer - Hospital São Vicente de Paulo</name>
      <address>
        <city>Passo Fundo</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da PUCRS</name>
      <address>
        <city>Pôrto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Câncer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base de São José do Rio Preto</name>
      <address>
        <city>São José do Rio Prêto</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa do Instituto Brasileiro de Controle do Câncer - IBCC</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ensino e Pesquisa São Lucas</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marcelina</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acıbadem City Clinic Cancer Center UMHAT</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Oncology Diseases Sofia District EOOD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Arturo López Pérez - Instituto Oncológico FALP</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health &amp; Care Spa</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Oncologico del Sur ICOS</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncocentro APYS</name>
      <address>
        <city>Viña del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Adjara Autonomous Republic</name>
      <address>
        <city>Batumi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acad. F . Todua medical center-research institute of clinical medicine</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consilium Medulla</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical Oncology</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD Aversi Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD Cancer Research Centre</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tbilisi State Medical Universitys First university Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Ippokratio&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sotiria General Hospital for Chest Diseases</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa</name>
      <address>
        <city>Lárisa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agioi Anargyroi General Oncological Hospital of Kifissia</name>
      <address>
        <city>Néa Kifisiá</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki &quot;George Papanikolaou&quot;</name>
      <address>
        <city>Thessaloníki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Koranyi Institute of TB and Pulmonology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Országos Korányi Pulmonológiai Intézet (OKPI)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkórháza</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veszprém Megyei Tüdőgyógyinzézet</name>
      <address>
        <city>Farkasgyepű</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zydus Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Action Cancer Hospital</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aadhar Health Institute</name>
      <address>
        <city>Hisar</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIMS - Nizam's Institute of Medical Sciences</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ganadhipati Purushottam Shekhawati Hospital Research Centre</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PVS Hospital Pvt Ltd</name>
      <address>
        <city>Kerola</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Gleneagles Hospital</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netaji Subhas Chandra Bose Cancer Research Institute</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shatabdi Super Speciality Hospital</name>
      <address>
        <city>Nashik</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital &amp; Research Center</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nirmal Hospital Pvt. Ltd.</name>
      <address>
        <city>Surat</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiran Super Multispeciality Hospital</name>
      <address>
        <city>Sūrat</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shree Himalaya Cancer Hospital Research Institute</name>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's NRI Hospital Gurudwara Lane</name>
      <address>
        <city>Visakhapatnam</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Notre Dame de Secours</name>
      <address>
        <city>Jbaïl</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>George Town</city>
        <state>Pulau Pinang</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Perubatan dan Pergigian Termaju Universiti Sains Malaysia</name>
      <address>
        <city>Kepala Batas</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusat Perubatan Universiti Kebangsaan Malaysia</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Umum Sarawak</name>
      <address>
        <city>Kuching</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Putrajaya</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose Eleuterio González</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baguio General Hospital &amp; Medical Center</name>
      <address>
        <city>Baguio</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cebu Doctors University Hospital - CDUH</name>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perpetual Succour Hospital - PSH</name>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>De La Salle University Medical Center - DLSUMC</name>
      <address>
        <city>Dasmariñas</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davao Doctors Hospital - DDH</name>
      <address>
        <city>Davao</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makati Medical Center</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital - PGH</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical City</name>
      <address>
        <city>Pasig</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center - Global City</name>
      <address>
        <city>Taguig</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI Arkhangelsk Region - Arkhangelsk Clinical Oncological Dispensary</name>
      <address>
        <city>Arkhangel'sk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional state budgetary Healthcare Institution &quot;Belgorod oncology dispensary&quot;</name>
      <address>
        <city>Belgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Healthcare Institution Ivanovo Regional Oncology Dispensary</name>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaluga Regional Clinical Oncology center</name>
      <address>
        <city>Kaluga</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republic Clinical Oncology Dispensary</name>
      <address>
        <city>Kazan'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kursk Republican Clinical Oncology Dispensary</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;VitaMed&quot; LLC</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Oncology Hospital No 62</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N. N. Blokhin Russian Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Headache Clinic LLC</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal budget Healthcare Institution &quot;Volga District Medical Centre&quot; under Federal Medical and Biological Agency</name>
      <address>
        <city>Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ of SK Pyatigorsk Oncology Dispensary</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Ryazan'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Oncology Dispensary</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ &quot;Leningrad Regional Clinical Hospital&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary healthcare Institution &quot;Samara regional clinical oncology dispensary&quot;</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC Bezanijska Kosa</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology and Radiology of Serbia (IORS)</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical center Nis (Clinic for pulmonary diseases)</name>
      <address>
        <city>Niš</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Pulmonary Diseases of Vojvodina</name>
      <address>
        <city>Sremska Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bangkok International Hospital And Wattanosod Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University (CMU) - Maharaj Nakhon Chiang Mai Hospital Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Rai Prachanukroh Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Hat Yai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddhachinaraj Hospital</name>
      <address>
        <city>Phitsanulok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Medeniyet University Medical Faculty</name>
      <address>
        <city>İstanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suat Seren Chest Diseases Hospital</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Cherkasy Regional Oncology Dispensary of Cherkasy Regional Council</name>
      <address>
        <city>Cherkasy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Higher Education Insititution of Ukraine &quot;Bukovinian State Medical University&quot;</name>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multifield Clinical Hospital No.4</name>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Dispensary</name>
      <address>
        <city>Dnipro</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Grigoriev Institute for Medical Radiology National Academy of Medical Science of Ukraine&quot;</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;V.T. Zaycev Institute of general and urgent surgery of National academy medical sciences of Ukraine&quot;</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical and Diagnostic Centre Private Enterprise of Private Manufacturing Company &quot;ACINUS&quot;</name>
      <address>
        <city>Kropyvnytskyi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Kryviy Rih Oncology Dispensary&quot; of Dnipropetrovsk Regional Council</name>
      <address>
        <city>Kryvyi Rih</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Cancer</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv State Oncology Regional Treatment and Diagnostic Center</name>
      <address>
        <city>L'viv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare facility &quot;Volyn regional Oncological Dispensary&quot;</name>
      <address>
        <city>Luts'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odessa Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzhgorod National University</name>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution &quot;Zaporizhzhya Regional Clinical Oncological Dispensary&quot; of Zaporizhzhya regional council</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Georgia</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Jordan</country>
    <country>Oman</country>
    <country>Peru</country>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>September 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2017</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

